Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension

被引：8
|
作者：
Koo, Rachel [1 ]
Lo, Jennifer [2 ]
Bock, Matthew J. [2 ]
机构：
[1] Loma Linda Univ Childrens Hlth, Dept Pediat, Loma Linda, CA USA
[2] Loma Linda Univ Childrens Hlth, Div Pediat Cardiol, Loma Linda, CA USA
来源：
CARDIOLOGY IN THE YOUNG | 2019年 / 29卷 / 06期
关键词：
Selexipag; infant; prostacyclin; pulmonary hypertension; paediatric;
D O I：
10.1017/S1047951119001082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.
引用
收藏
页码：849 / 851
页数：3
相关论文
共 50 条
  • [31] Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
    Alexandre, Andre
    Furtado, Ines
    Carvalho, Luisa
    Goncalves, Fabienne
    Melo, Alzira
    Alves, Joana
    Santos, Mario
    Reis, Abilio
    ESC HEART FAILURE, 2023, 10 (04): : 2722 - 2727
  • [32] Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension
    Ferrantino, Matthew
    White, R. James
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (16) : 2583 - 2593
  • [33] Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension
    Grossman, Madeline
    Walker, Stephen
    Ramsey, E. Zachary
    PEDIATRIC CARDIOLOGY, 2024, : 902 - 907
  • [34] Transitioning Parenteral Prostacyclin Analogs to Selexipag in Pulmonary Arterial Hypertension
    Shelburne, Nicholas J.
    Parikh, Kishan S.
    Kennedy, Karla
    Dahhan, Talal
    Fortin, Terry
    Rajagopal, Sudarshan
    CIRCULATION, 2018, 138
  • [35] Selexipag in the management of pulmonary arterial hypertension: an update
    Coghlan, J. Gerry
    Picken, Christina
    Clapp, Lucie H.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2019, 11 : 55 - 64
  • [36] Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
    Hardin, Elizabeth Ashley
    Chin, Kelly M.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3747 - 3754
  • [37] Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
    Ivy, D. Dunbar
    Feinstein, Jeffrey A.
    Yung, Delphine
    Mullen, Mary P.
    Kirkpatrick, Edward C.
    Hirsch, Russel
    Austin, Eric D.
    Fineman, Jeffrey
    Truong, Uyen
    Solum, Derek
    Deng, C. Q.
    Hopper, Rachel K.
    PULMONARY CIRCULATION, 2019, 9 (03)
  • [38] Oral treprostinil diethanolamine for pulmonary arterial hypertension
    Feldman, Jeremy
    Im, Yunhee
    Gill, Kirat
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (01) : 55 - 60
  • [39] Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension
    Sardana, Mayank
    Moll, Matthew
    Farber, Harrison W.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (12) : 1513 - 1520
  • [40] Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension
    Poms, Abby
    Kingman, Martha
    CRITICAL CARE NURSE, 2011, 31 (06) : E1 - E11
12345